Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A study analyzed how well people with HIV and their health care providers can navigate the experimental long-acting injectable Cabenuva.
Bamlanivimab is now authorized for nonhospitalized people at high risk for progressing to severe COVID-19.
Long-acting injectable cabotegravir for HIV prevention could hit the market for men and women in early 2022.
The antiviral drug is the first treatment for the new coronavirus to be approved in United States.
The novel attachment inhibitor led to viral suppression in 60% of people with extensive prior treatment.
The new credit card-size rapid antigen test can return results in 15 minutes.
“The SalivaDirect test...is yet another testing innovation game changer that will reduce the demand for scarce testing resources.”
The immune modulator Pomalyst led to remission in two thirds of people with AIDS-related Kaposi sarcoma.
The single-tablet regimen is now approved for previously treated people with an undetectable viral load.
The agency has also lowered the weight threshold for film-coated tablets of the integrase inhibitor.
The immune modulator Pomalyst led to remission in two thirds of people with AIDS-related KS.
Whether given every four or eight weeks, long-acting injections of cabotegravir and rilpivirine suppressed HIV equally well.
Tests like the one approved this week can show who is likely to be immune, but it’s not yet clear how long such immunity lasts.
ViiV applies for FDA approval of HIV drug fostemsavir
The Food and Drug Administration declined approval of ViiV Healthcare’s injectable HIV regimen Cabenuva.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.